Literature DB >> 25022588

Antistaphylococcal activity of oritavancin and its synergistic effect in combination with other antimicrobial agents.

Gengrong Lin1, Glenn Pankuch1, Peter C Appelbaum1, Klaudia Kosowska-Shick2.   

Abstract

Oritavancin exhibited in vitro activity against 169 strains of vancomycin-susceptible, methicillin-resistant Staphylococcus aureus (MRSA) with MICs ranging from 0.03 to 1 μg/ml and against vancomycin-intermediate MRSA (VISA; n = 29), heterogeneous vancomycin-intermediate MRSA (hVISA; n = 5), and vancomycin-resistant MRSA (n = 5) strains, with MICs ranging from 0.12 to 4 μg/ml. For 10 MRSA isolates comprising 5 VISA and 5 hVISA strains, synergy between oritavancin and gentamicin, linezolid, or rifampin was observed against most of the strains tested using a time-kill method.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25022588      PMCID： PMC4187905          DOI： 10.1128/AAC.02932-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis.

Authors:  Kathleen Julian; Klaudia Kosowska-Shick; Cynthia Whitener; Martin Roos; Harald Labischinski; Aileen Rubio; Leslie Parent; Lois Ednie; Laura Koeth; Tatiana Bogdanovich; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2007-07-09       Impact factor: 5.191

2.  Comparative in vitro activity of oritavancin against Staphylococcus aureus strains that are resistant, intermediate or heteroresistant to vancomycin.

Authors:  Francis F Arhin; Ingrid Sarmiento; Thomas R Parr; Gregory Moeck
Journal:  J Antimicrob Chemother       Date:  2009-08-04       Impact factor: 5.790

3.  Incidence and characteristics of vancomycin nonsusceptible strains of methicillin-resistant Staphylococcus aureus at Hershey Medical Center.

Authors:  Klaudia Kosowska-Shick; Lois M Ednie; Pamela McGhee; Kathy Smith; Cynthia D Todd; Amanda Wehler; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2008-10-06       Impact factor: 5.191

4.  Comparative in vitro activity of oritavancin against recent, genetically diverse, community-associated meticillin-resistant Staphylococcus aureus (MRSA) isolates.

Authors:  Francis F Arhin; Natalia Kurepina; Ingrid Sarmiento; Thomas R Parr; Gregory Moeck; Barry Kreiswirth
Journal:  Int J Antimicrob Agents       Date:  2009-09-09       Impact factor: 5.283

5.  Mechanisms of daptomycin resistance in Staphylococcus aureus.

Authors:  Glenn W Kaatz; Tammy S Lundstrom; Susan M Seo
Journal:  Int J Antimicrob Agents       Date:  2006-09-11       Impact factor: 5.283

6.  Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.

Authors:  Francis F Arhin; Deborah C Draghi; Chris M Pillar; Thomas R Parr; Gregory Moeck; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2009-09-08       Impact factor: 5.191

Review 7.  Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.

Authors:  Benjamin P Howden; John K Davies; Paul D R Johnson; Timothy P Stinear; M Lindsay Grayson
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

8.  Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.

Authors:  Geoffrey A McKay; Sylvain Beaulieu; Francis F Arhin; Adam Belley; Ingrid Sarmiento; Thomas Parr; Gregory Moeck
Journal:  J Antimicrob Chemother       Date:  2009-04-15       Impact factor: 5.790

9.  Assessment by time-kill methodology of the synergistic effects of oritavancin in combination with other antimicrobial agents against Staphylococcus aureus.

Authors:  Adam Belley; Eve Neesham-Grenon; Francis F Arhin; Geoffrey A McKay; Thomas R Parr; Gregory Moeck
Journal:  Antimicrob Agents Chemother       Date:  2008-07-21       Impact factor: 5.191

10.  Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant staphylococcus aureus infection.

Authors:  Adam Belley; Francis F Arhin; Ingrid Sarmiento; Hong Deng; Warren Rose; Greg Moeck
Journal:  Antimicrob Agents Chemother       Date:  2012-10-22       Impact factor: 5.191
View more
  8 in total

1.  Results from Oritavancin Resistance Surveillance Programs (2011 to 2014): Clarification for Using Vancomycin as a Surrogate To Infer Oritavancin Susceptibility.

Authors:  Ronald N Jones; Greg Moeck; Francis F Arhin; Michael N Dudley; Paul R Rhomberg; Rodrigo E Mendes
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

Review 2.  Oritavancin: a review in acute bacterial skin and skin structure infections.

Authors:  Yahiya Y Syed; Lesley J Scott
Journal:  Drugs       Date:  2015-11       Impact factor: 9.546

Review 3.  Oritavancin for acute bacterial skin and skin structure infections.

Authors:  Julia A Messina; Vance G Fowler; G Ralph Corey
Journal:  Expert Opin Pharmacother       Date:  2015-03-24       Impact factor: 3.889

Review 4.  New Perspectives on Antimicrobial Agents: Long-Acting Lipoglycopeptides.

Authors:  Truc T Tran; Sara Gomez Villegas; Samuel L Aitken; Susan M Butler-Wu; Alex Soriano; Brian J Werth; Jose M Munita
Journal:  Antimicrob Agents Chemother       Date:  2022-04-27       Impact factor: 5.938

Review 5.  Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.

Authors:  Françoise Van Bambeke
Journal:  Drugs       Date:  2015-12       Impact factor: 9.546

6.  Evaluation of Oritavancin Combinations with Rifampin, Gentamicin, or Linezolid against Prosthetic Joint Infection-Associated Methicillin-Resistant Staphylococcus aureus Biofilms by Time-Kill Assays.

Authors:  Qun Yan; Melissa J Karau; Yash S Raval; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

7.  Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.

Authors:  Jordan R Smith; Juwon Yim; Animesh Raut; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

8.  New agents approved for treatment of acute staphylococcal skin infections.

Authors:  Jan Tatarkiewicz; Anna Staniszewska; Magdalena Bujalska-Zadrożny
Journal:  Arch Med Sci       Date:  2016-05-11       Impact factor: 3.318
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.